key: cord-0882263-642d5bue
authors: Lin, Wei‐Ting; Hung, Shun‐Hsing; Lai, Chih‐Cheng; Wang, Cheng‐Yi; Chen, Chao‐Hsien
title: The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials
date: 2022-02-07
journal: J Med Virol
DOI: 10.1002/jmv.27623
sha: d47daa977e1dda260f961974d2d030c136aabd2a
doc_id: 882263
cord_uid: 642d5bue

To assess the clinical efficacy and safety of neutralizing monoclonal antibodies (mABs) for outpatients with coronavirus disease 2019 (COVID‐19). PubMed, Embase, Web of Science, Cochrane Library, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (ICTRP) databases were searched from inception to July 19, 2021. Only randomized controlled trials (RCTs) that assessed the clinical efficacy and safety of neutralizing mABs in the treatment of COVID‐19 outpatients were included. The Cochrane risk‐of‐bias tool was used to assess the quality of the included RCTs. The primary outcome was the risk of COVID‐19‐related hospitalization or emergency department (ED) visits. The secondary outcomes were the risk of death and adverse events (AEs). Five articles were included, in which 3309 patients received neutralizing mAB and 2397 patients received a placebo. A significantly lower rate of hospitalization or ED visits was observed among patients who received neutralizing mABs than those who received a placebo (1.7% vs. 6.5%, odds ratios (OR): 0.26; 95% confidence interval (CI): 0.19–0.36; I (2) = 0%). In addition, the rate of hospitalization was significantly lower in the patients who received neutralizing mABs than in the control group (OR: 0.24; 95% CI: 0.17−0.34; I (2) = 0%). The mortality rate was also significantly lower in the patients who received neutralizing mABs than in the control group (OR: 0.16; 95% CI: 0.05−0.58; I (2) = 3%). Neutralizing mABs were associated with a similar risk of any AE (OR: 0.81; 95% CI: 0.64–1.01; I (2) = 52%) and a lower risk of serious AEs (OR: 0.37; 97% CI: 0.19–0.72; I (2) = 45%) compared with a placebo. Neutralizing mABs can help reduce the risk of hospitalization or ED visits in COVID‐19 outpatients. For these patients, neutralizing mABs are safe and not associated with a higher risk of AEs than a placebo.

On March 11, 2020 , the World Health Organization (WHO) declared that coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was a global pandemic due to the rapidly increasing number of infected people worldwide. 1 As of August 12, 2021 , there have been more than 203 million confirmed cases of COVID-19, including more than 4.3 million deaths globally. 2 Although the newly developed vaccines can provide effective protection against SARS-CoV-2 infection, 3 many new COVID-19 cases have been reported recently. Therefore, the increasing number of COVID-19 patients remains a critical public health concern. The clinical spectrum of COVID-19 can range from asymptomatic status, acute respiratory disease, pneumonia, to acute respiratory distress syndrome. [4] [5] [6] Currently, the recommended treatment options for COVID-19 patients depend on the stage and severity of the disease. [5] [6] [7] For hospitalized COVID-19 patients, antiviral agents such as remdesivir is suggested, however, antiinflammatory agents such as corticosteroids and anti-interleukin-6 are recommended for patients requiring high-flow oxygen/noninvasive ventilation therapy with evidence of clinical progression or increased markers of inflammation. [7] [8] [9] In addition to patients with severe to critical COVID-19, a significant number of patients are classified as having mild or moderate illness, some of whom may progress to severe illness or require hospitalization, particularly those with older age, multiple comorbidities, obesity, or immunocompromised status. 6 (including neutralizing mABs, etesevimab, bamlanivimab, casirivimab, imdevimab, JS016, TY027, BRII-196, BRII-198, ABBV-47D11, STI-1499, MW33, HFB30132A,   ADM03820, HLX70, DZIF-10c, STI-2020, BGB DXP593, SCTA01,   AZD8895, AZD1061, CT-P59, VIR- (Table S1 ). We also manually searched for additional eligible articles from the reference lists of relevant articles and preprint server of medRxiv. Studies were included if they met the following was consulted and made the final decision in cases of disagreement over the same publication. The following data were extracted separately by two authors from each included study: year of publication, study design, the regimen of the neutralizing mABs, clinical outcomes, and risk of AEs.

A third author was consulted and discussed if the extracted data was inconsistent. This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. 21 The protocol of the systematic review and meta-analysis was registered at PROSPERO (CRD42021268377).

The primary outcome was the risk of COVID-19-related hospitalization or emergency department (ED) visits. The secondary outcomes were the risk of death and the risk of AEs.

The Cochrane risk-of-bias tool 22 was used to assess the quality of the included RCTs and their associated risk of bias. Two reviewers subjectively reviewed all included studies and rated them as being "low risk," "high risk," or "unclear" independently. Any disagreement was resolved by a third reviewer who made the final decision. Statistical analyses were performed using Review Manager (version 5.3; Nordic Cochrane Centre). The degree of heterogeneity was evaluated using Q statistics generated from the χ 2 test, and the I 2 measure was used to assess statistical heterogeneity. Heterogeneity was defined as significant when p < 0.10 or I 2 > 50%. A fixed-effects model was used

when the data were homogeneous, and a random-effects model was used when the data were heterogeneous. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for outcome analysis. The sensitivity analysis was performed using a leave-oneout approach. The subgroup analysis including different neutralizing mABs regimens and high risk patients for hospitalization were also conducted.

The search of the online databases yielded a total of 405 studies, of which 170 duplicate studies were excluded. In addition, 186 studies were judged to be irrelevant after screening the titles, abstracts, and publications with no full text available. Furthermore, 43 studies were excluded after the full texts of 49 articles were screened. Finally, five articles [14] [15] [16] 19, 20 were included in this meta-analysis ( Figure 1 ).

Unpublished or ongoing studies are summarized in Table S2 .

All of the articles were multicenter studies, and three were multinational studies 16, 19, 20 (Table 1) 

The rate of COVID-19-related hospitalization or ED visits in the patients who received neutralizing mABs was only 1.7% (57/3309), which was much lower than that of the controls who received a placebo (6.5%, 155/2397). A significant difference in the rate of hospitalization or ED visits was observed between the patients who received neutralizing mABs and those who received a placebo (OR: 0.26; 95% CI: 0.19−0.36; I 2 = 0%, Figure 3 ). This difference remained significant in the leave-one-out sensitivity test, in which individual studies were randomly excluded. In the subgroup analysis, neutralizing mAB treatment was associated with a lower risk of hospitalization or ED visits than a placebo among high-risk patients 

Two of 3209 patients who received neutralizing mABs died compared to 14 of 3041 patients in the control group. The mortality rate was significantly lower in the neutralizing mABs group than in the control group (OR: 0.16; 95% CI: 0.05−0.58; I 2 = 3%) in the pooled analysis of four RCTs 14, 15, 19, 20 which reported mortality as an outcome (Figure 4 ).

Regarding the risk of AEs, neutralizing mABs were associated with a similar risk of any AE as the control group (OR: 0.81; 95% CI: 0.64-1.01; I 2 = 52%, Figure 5 ). This similarity persisted regardless of the Figure 5 ). Moreover, no significant differences were noted between those who received neutralizing mABs and those who received a placebo in the risk of nausea 

In this meta-analysis, five articles [14] [15] [16] 19, 20 imdevimab significantly reduced the duration of a high viral load in the overall study population (39.7% reduction vs. placebo; 48 vs. 82 total weeks; p = 0.0010). 16 Taken together, these findings indicate that neutralizing mABs can accelerate the reduction of SARS-CoV-2 viral load and help reduce the risk of further hospitalization.

Finally, we assessed safety issues associated with neutralizing mABs. The analysis showed that neutralizing mABs were not associated with a higher risk of AEs than a placebo, including any AE and serious AEs. Moreover, no significant difference was observed between neutralizing mABs and the comparators for specific AEs including nausea, vomiting, diarrhea, dizziness, headache, rash, and pruritis. These findings indicate that neutralizing mABs are safe for the treatment of COVID-19 patients.

This meta-analysis had several limitations. First, the numbers of studies and patients were small, especially for each neutralizing mAB.

Second, because of the lack of available data, we could not evaluate the effect of neutralizing mABs according to different SARS-CoV-2 variants, especially for Omicron (B.1.1.529). One study 28 using SARS-CoV-2 virus-like particles (VLP) found that no activity was detected for casirivimab or imdevimab either against Omicron VLPs. Moreover, casirivimab was able to neutralize OmC3 but not OmC1 and imdevimab was able to neutralize OmC1 but not OmC3. All these findings suggested that the failure of these mABs to neutralize Omicron S could be due to the six mutations within the Omicron RBD (K417N, N440K, G446S, G496S, Q498R, and N501Y). 28 Another study using an artificial intelligence model predicted that the efficacy of several neutralizing mABs, such as bamlanivimab and etesevimab, casirivimab and imdevimab against Omicron might largely diminish but the impact of Omicron on the activity of sotrovimab could be mild. 29 The similar findings that bamlanivimab and etesevimab, casirivimab and imdevimab completely lost neutralizing activity against Omicron whereas sotrovimab was only minimally affected, were also reported in an in vitro study in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells. 30 Third, the risk of mutations leading to neutralizing mAB resistance remains a serious concern, particularly for bamlanivimab. 15, [31] [32] [33] In one study 33 Fourth, this study only focused on the usefulness of neutralizing mABs in COVID-19 outpatients, however available information about their clinical efficacy in COVID-19 in patients is limited. 17, 34 Further studies are warranted to clarify these issues. Finally, many ongoing studies are currently investigating the efficacy of neutralizing mABs, 31,32 and more evidence will be available in the near feature.

In conclusion, neutralizing mABs can help reduce the risk of hospitalization or ED visits for COVID-19 outpatients. For these patients, neutralizing mABs are safe and not associated with a higher risk of AEs than a placebo. However, there could be a new serious concern about the diminished activities of most of these neutralizing mABs against the new SARS-CoV-2 variant-Omicron. 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges

World Health Organization. WHO coronavirus (COVID-19) dashboard

COVID-19 vaccines: concerns beyond protective efficacy and safety

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths

Severe Covid-19

Mild or moderate Covid-19

COVID-19) treatment guidelines; 2021

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Neutralizing monoclonal antibodies for treatment of COVID-19

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Bamlanivimab plus etesevimab in mild or moderate Covid-19

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial

A neutralizing monoclonal antibody for hospitalized patients with Covid-19

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab

REGEN-COV antibody combination and outcomes in outpatients with Covid-19

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Cochrane collaboration's tool for assessing risk of bias in randomised trials

Real-world experience of bamlanivimab for COVID-19: a case-control study

Effectiveness of severe acute respiratory syndrome coronavirus 2 monoclonal antibody infusions in high-risk outpatients

Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial

Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19. medRxiv

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 viruslike particles. medRxiv

Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Neutralizing antibody therapeutics for COVID-19

Tackling COVID-19 with neutralizing monoclonal antibodies

Emergence of SARS-CoV-2 resistance with monoclonal antibody therapy

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv

The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials

The author declares that there are no conflicts of interest.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

http://orcid.org/0000-0002-6334-2388Chao-Hsien Chen http://orcid.org/0000-0002-2176-3504